InSightec tests ExAblate therapy in liver and bone cancer trials:
This article was originally published in Clinica
Executive Summary
Israel-based InSightec has initiated two clinical trials in Europe evaluating the benefit of its ExAblate 2000 ablation therapy as a treatment for liver cancer and pain palliation in metastatic bone tumours. Up to 20 patients will be recruited onto each trial, which will be conducted at the Charite Hospital in Berlin, Germany, and St Mary's Hospital in London, UK. ExAblate 2000 uses MRI-guided high-focused ultrasound (MRgFUS) to thermally ablate tissue without the need for surgery. To date, the system, which is compatible with GE Healthcare's Signa MR system, is only approved to treat uterine fibroids.
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.